PanTera: most promising alpha-emitting radioisotopes to fight cancers
- Client
- Pantera SA/NV, a joint venture between IBA, the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre
- Country
- Belgium
- Period
- 2024 - Ongoing
The Challenge
Bringing new hope to cancer patients is now part of how Tractebel engineers solutions for clients. Pantera SA/NV challenged us to design and build an actinium-225 production facility in Belgium, one of the most promising alpha-emitting radioisotopes to fight cancers. They chose Tractebel because of our 60 years of excellence in the nuclear sector and record of building facilities that meet all safety and security requirements.
The Solution
Tractebel is designing the new facility and providing engineering services in the fields of structural engineering, heating, ventilation and air conditioning (HVAC), electricity, fire protection, instrumentation & control (I&C), mechanical and more.
Tractebel is also supporting PanTera during the construction. During all phases, Tractebel will leverage its radioprotection and nuclear expertise to integrate specific production equipment such as the particle accelerator, target stations and hot cells. This is a joint project with MODULO architects.
The Impact
Our work will secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to improve the accessibility of innovative cancer therapies.
"Our collaboration with Tractebel and MODULO brings unmatched expertise as we can leverage their unique multi-disciplinary teams. We have now secured partnerships with leading engineering companies to support all our process and infrastructure development. As a result, we are poised to ensure the extensive availability of Ac-225, enabling promising therapies to be made available to cancer patients."
Sven Van den Berghe
Chief Executive Officer, PanTera